Your browser is no longer supported. Please, upgrade your browser.
NeoGenomics, Inc.
Index- P/E67.63 EPS (ttm)0.35 Insider Own2.80% Shs Outstand122.56M Perf Week-15.00%
Market Cap2.89B Forward P/E- EPS next Y-0.51 Insider Trans-3.08% Shs Float117.85M Perf Month-25.90%
Income48.80M PEG5.50 EPS next Q-0.14 Inst Own96.10% Short Float5.60% Perf Quarter-46.39%
Sales484.60M P/S5.96 EPS this Y-51.70% Inst Trans0.05% Short Ratio7.33 Perf Half Y-47.02%
Book/sh9.28 P/B2.52 EPS next Y-88.50% ROA3.10% Target Price48.82 Perf Year-56.48%
Cash/sh4.40 P/C5.32 EPS next 5Y12.30% ROE5.10% 52W Range24.03 - 61.57 Perf YTD-31.42%
Dividend- P/FCF- EPS past 5Y23.30% ROI0.30% 52W High-61.99% Beta0.71
Dividend %- Quick Ratio7.40 Sales past 5Y34.80% Gross Margin41.10% 52W Low-2.62% ATR1.78
Employees1700 Current Ratio7.70 Sales Q/Q-3.30% Oper. Margin-14.80% RSI (14)23.66 Volatility5.78% 5.95%
OptionableYes Debt/Eq0.47 EPS Q/Q-536.70% Profit Margin10.10% Rel Volume1.19 Prev Close24.94
ShortableYes LT Debt/Eq0.47 EarningsNov 04 BMO Payout0.00% Avg Volume900.49K Price23.40
Recom1.70 SMA20-25.12% SMA50-32.24% SMA200-44.93% Volume1,068,822 Change-6.17%
Jan-18-22Resumed Stephens Overweight $40
Dec-16-21Initiated Cowen Outperform $42
Nov-05-21Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-14-21Upgrade Raymond James Mkt Perform → Outperform $53
Jun-03-21Initiated Goldman Buy $55
Feb-25-21Resumed Needham Buy $65
Feb-25-21Downgrade Raymond James Outperform → Mkt Perform
Jan-28-21Initiated Truist Buy $65
Dec-11-20Resumed BTIG Research Buy $60
Oct-28-20Reiterated Needham Buy $39 → $46
Sep-09-20Initiated Morgan Stanley Overweight $46
Aug-28-20Initiated Guggenheim Buy $46
Jul-29-20Reiterated Needham Buy $33 → $39
Jun-25-20Initiated BofA/Merrill Buy $34
Apr-21-20Resumed Stephens Overweight $33
Mar-02-20Resumed Craig Hallum Buy $38
Feb-28-20Upgrade First Analysis Sec Outperform → Strong Buy
Jan-23-20Downgrade First Analysis Sec Strong Buy → Outperform $29 → $35
Oct-30-19Reiterated Needham Buy $27 → $29
May-01-19Reiterated Needham Buy $22 → $24
Jan-11-22 07:00AM  
Dec-29-21 03:58PM  
Dec-13-21 02:00AM  
Dec-11-21 06:38AM  
Dec-10-21 07:00AM  
Dec-07-21 12:15AM  
Nov-30-21 07:00AM  
Nov-23-21 11:11AM  
Nov-10-21 07:00AM  
Nov-08-21 05:00AM  
Nov-06-21 01:30PM  
Nov-04-21 10:55AM  
Oct-28-21 03:05PM  
Oct-19-21 02:00AM  
Oct-13-21 04:20PM  
Oct-12-21 04:05PM  
Oct-01-21 01:13PM  
Sep-09-21 07:00AM  
Sep-06-21 01:14PM  
Sep-01-21 04:05PM  
Aug-23-21 08:56AM  
Aug-13-21 12:53PM  
Aug-06-21 05:30PM  
Jul-30-21 03:00PM  
Jul-14-21 04:05PM  
Jun-21-21 08:04AM  
Jun-18-21 10:34PM  
Jun-08-21 08:01AM  
May-27-21 04:05PM  
May-25-21 04:44AM  
May-18-21 12:33PM  
May-12-21 09:02AM  
May-11-21 09:11AM  
May-10-21 04:15PM  
May-09-21 08:30AM  
May-05-21 06:01PM  
Apr-28-21 12:34PM  
Apr-19-21 07:00AM  
Apr-16-21 05:15AM  
Apr-13-21 07:00AM  
Apr-07-21 04:05PM  
Apr-01-21 06:05AM  
Mar-24-21 10:04AM  
Mar-16-21 07:00AM  
Mar-01-21 07:00AM  
Feb-25-21 07:00AM  
Feb-24-21 02:30PM  
Feb-16-21 07:00AM  
Feb-05-21 07:00AM  
Feb-04-21 07:00AM  
Feb-02-21 08:00AM  
Jan-10-21 11:00AM  
Jan-06-21 11:00PM  
Jan-05-21 04:05PM  
Jan-04-21 07:30AM  
Dec-16-20 05:33PM  
Nov-29-20 06:44AM  
Nov-16-20 08:00AM  
Nov-13-20 04:05PM  
Nov-09-20 07:00AM  
Oct-29-20 09:34AM  
Oct-28-20 10:58AM  
Oct-27-20 02:00PM  
Oct-20-20 12:31PM  
Oct-15-20 09:00AM  
Oct-13-20 01:31PM  
Oct-01-20 07:00AM  
Sep-10-20 04:05PM  
Sep-07-20 11:40AM  
Aug-31-20 05:00PM  
Aug-28-20 10:16AM  
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited; and has collaboration with Elevation Oncology to expand genomic testing for NRG1 fusions across solid tumors. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McKenzie Kathryn BChief Sustainability/Risk OfcrJan 11Option Exercise9.072,10019,04749,361Jan 12 06:50 PM
Johnson Kevin CDirectorDec 22Option Exercise7.273,33424,23837,398Dec 23 05:25 PM
McKenzie Kathryn BChief Financial OfficerDec 22Option Exercise9.075,00045,35016,689Dec 23 05:25 PM
McKenzie Kathryn BChief Financial OfficerDec 21Sale35.001,84664,61011,689Dec 23 05:25 PM
Mallon MarkChief Executive OfficerDec 06Buy30.6317,000520,71072,736Dec 06 04:16 PM
Bonello WilliamPresident, InformaticsNov 30Option Exercise7.5225,000188,00040,473Dec 02 06:09 PM
Brown Douglas MatthewChief Strategy OfficerNov 26Sale36.8533,3341,228,35811,644Nov 26 04:14 PM
Bonello WilliamPresident, InformaticsNov 24Option Exercise8.0325,000200,75040,473Nov 29 04:16 PM
Bonello WilliamPresident, InformaticsNov 24Sale37.1325,000928,25015,473Nov 29 04:16 PM
Brown Douglas MatthewChief Strategy OfficerNov 24Sale36.8433,3331,227,98844,978Nov 26 04:14 PM
Brown Douglas MatthewChief Strategy OfficerNov 23Sale37.1933,3331,239,65478,311Nov 26 04:14 PM
CROWTHER BRUCE KDirectorJun 08Option Exercise14.5820,734302,24170,298Jun 10 05:01 PM
CROWTHER BRUCE KDirectorJun 08Sale41.4620,734859,63249,564Jun 10 05:01 PM
CARDOZA GEORGEPresident, Pharma ServicesJun 03Sale40.1131,1071,247,702176,772Jun 04 07:56 PM
CARDOZA GEORGEPresident, Pharma ServicesJun 02Sale40.39169,2306,835,200207,879Jun 04 07:56 PM
SHOVLIN ROBERT J.President, Clinical ServicesMay 25Option Exercise11.80126,9581,498,530280,705May 27 06:23 PM
SHOVLIN ROBERT J.President, Clinical ServicesMay 25Sale39.31130,6045,134,043150,101May 27 06:23 PM
Weiss Lawrence MartinChief Medical OfficerApr 22Option Exercise20.1125,050503,646130,847Apr 26 05:48 PM